Cidara Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Cidara Therapeutics (NASDAQ: CDTX) announced that Jeffrey Stein, Ph.D., the President and CEO, will participate in two upcoming investor conferences. The first is the Cantor Fitzgerald Future of Oncology Virtual Symposium on April 3, 2023, at 11:00 am ET, where he will take part in a panel discussion. The second event is the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 12:45 pm ET, featuring a presentation and one-on-one investor meetings. Cidara's presentation at the Needham Conference will be available on-demand, with a replay accessible for 90 days. The company focuses on long-acting therapeutics for serious diseases.

SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, is scheduled to participate in the following upcoming investor conferences.

Event: Cantor Fitzgerald Future of Oncology Virtual Symposium
Format: Panel Discussion
Date: Monday, April 3, 2023
Time: 11:00am ET

Event: 22^nd Annual Needham Virtual Healthcare Conference
Format: Presentation and 1x1 Investor Meetings
Date: Monday, April 17, 2023
Time: 12:45pm ET
Webcast: https://wsw.com/webcast/needham129/cdtx/2262858

Cidara’s presentation at the Needham Conference will be available on-demand from the above date/time in the investors section on the Company’s website at www.cidara.com. The replay of the presentation will be available for 90 days.

About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The company’s portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including drug-Fc conjugates (DFCs) from its proprietary Cloudbreak^® platform targeting oncologic and viral diseases. In addition, Cidara recently received FDA approval for REZZAYO™ (rezafungin for injection), which it has licensed to multiple partners to commercialize in the U.S. and ex-U.S. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

MEDIA CONTACT:
Veronica Eames
LifeSci Communications
(646) 970-4682
veames@lifescicomms.com

FAQ

When is Cidara Therapeutics participating in the Cantor Fitzgerald Future of Oncology Virtual Symposium?

Cidara Therapeutics will participate in the Cantor Fitzgerald Future of Oncology Virtual Symposium on April 3, 2023, at 11:00 am ET.

What will Jeffrey Stein present at the Needham Virtual Healthcare Conference?

Jeffrey Stein will present and participate in one-on-one investor meetings at the Needham Virtual Healthcare Conference on April 17, 2023.

How can I access Cidara's presentation from the Needham Conference?

Cidara's presentation from the Needham Conference will be available on-demand on their website starting April 17, 2023, and the replay will be accessible for 90 days.

What is the focus of Cidara Therapeutics?

Cidara Therapeutics focuses on developing long-acting therapeutics aimed at improving the standard of care for patients with serious diseases.

What recent FDA approval has Cidara Therapeutics received?

Cidara Therapeutics recently received FDA approval for REZZAYO™ (rezafungin for injection), which it has licensed to various partners for commercialization.